Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB:RVVTF) (CNSX:RVV.CN) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and […]
Tryp Therapeutics to Host Q3 Investor Day on July 29, 2021
San Diego, California–(Newsfile Corp. – July 15, 2021) – Tryp Therapeutics (CNSX:TRYP.CN) (OTCQB:TRYPF) (“Tryp”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will host their Q3 Investor Day on July 29, 2021 at 9:00 a.m. PDT. The event will include a presentation by Tryp’s […]
